Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens
AssigneeThe Scripps Research Institute
InventorsLinling He, Jiang Zhu, Ian A. Wilson, Yi-Zong Lee
Life of this patent
Estimating the term…
Abstract
The present invention provides novel engineered influenza hemagglutinin (HA) proteins, related polynucleotide sequences, and vaccine compositions including nanoparticle compositions. Relative to a wildtype HA protein, the engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating influenza viral infections.
Claims23
An engineered influenza viral hemagglutinin (HA) protein, comprising a modified HA2 ectodomain, wherein the modified HA2 ectodomain comprises substitution of the amino acid residue at position 95 or at position 106 with a hydrophobic residue;
- wherein amino acid numbering of HA2 is based on Influenza A Subtype H3.
Dependencies are inferred from the claim text.